You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Orchid Pharma rallies 7.21% in two sessions

Capital Market 

Orchid Pharma rose 1.78% to Rs 37.20 at 14:21 on BSE, with the stock extending yesterday's rally after receiving the Establishment Inspection Report from the United States Food and Drug Administration.

Meanwhile, the S&P Sensex was down 10.01 points, or 0.03% at 29,329.11. The S&P Small-cap index was up 63.91 points, 0.43% at 14,908.02.

On the BSE, 3.43 lakh shares were traded on the counter so far as against the average daily volumes of 1.99 lakh shares in the past one quarter. The stock had hit a high of Rs 37.90 and a low of Rs 36.75 so far during the day.

The stock had hit a 52-week high of Rs 45.90 on 22 April 2016 and a 52-week low of Rs 23.70 on 22 November 2016. The stock had outperformed the market over the past one month till 18 April 2017, advancing 30.07% compared with the Sensex's 1.11% decline. The scrip had also outperformed the market over the past one quarter advancing 28.02% as against the Sensex's 7.56% rise.

The small-cap company has equity capital of Rs 88.96 crore. Face value per share is Rs 10.

Shares of Orchid Pharma have rallied 7.21% in two trading sessions from its close of Rs 34.70 on 17 April 2017, after the company announced during market hours yesterday, 18 April 2017, that it received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) based on the successful inspection of the formulation manufacturing facility located in Kancheepuram District, Tamil Nadu. The facility was inspected by USFDA in December 2016. The stock had rallied 5.33% to settle at Rs 36.55 yesterday, 18 April 2017.

Separately, Orchid Pharma said that Credit Analysis & Research (CARE) has revised the ratings on the long-term bank facilities of the company to CARE D from CARE B-. It has revised the ratings on the short-term bank facilities of the company to CARE D from CARE A4.

The revision in ratings assigned to the bank facilities of Orchid Pharma takes into account instances of delay in debt servicing. The announcement was made after market hours on Monday, 17 April 2017.

Orchid Pharma reported net loss of Rs 60.98 crore in Q3 December 2016, compared with net loss of Rs 94.02 crore in Q3 December 2015. Net sales declined 13.1% to Rs 177.27 crore in Q3 December 2016 over Q3 December 2015.

Orchid Pharma is a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU